Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia: A randomised, heparin-controlled pilot study

Elisabetta Cofrancesco, Carla Boschetti, Patrizia Leonardi, Francesco Gianese, Michele Cortellaro

Research output: Contribution to journalArticle

Abstract

Efficacy and safety of i.v. dermatan sulphate (DS) and heparin (H) in controlling laboratory alterations due to DIC were compared in 10 patients with acute leukaemia, in a prospective, randomised pilot study. The time courses of the coagulation and fibrinolysis markers for DIC were similar in the two treatment groups except for activated partial thromboplastin time and thrombin time, which were prolonged in the H but not in the DS group. Blood product support tended to be greater in the H than in the DS group. DS appears to be as effective as H in controlling thrombin production during leukaemic cytolysis and may represent a safer alternative to H in the management of DIC in acute leukaemia.

Original languageEnglish
Pages (from-to)65-75
Number of pages11
JournalThrombosis Research
Volume74
Issue number1
DOIs
Publication statusPublished - Apr 1 1994

Fingerprint

Dermatan Sulfate
Disseminated Intravascular Coagulation
Heparin
Leukemia
Thrombin Time
Partial Thromboplastin Time
Fibrinolysis
Therapeutics
Thrombin
Safety

Keywords

  • acute leukaemia
  • dermatan sulphate
  • DIC
  • heparin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia : A randomised, heparin-controlled pilot study. / Cofrancesco, Elisabetta; Boschetti, Carla; Leonardi, Patrizia; Gianese, Francesco; Cortellaro, Michele.

In: Thrombosis Research, Vol. 74, No. 1, 01.04.1994, p. 65-75.

Research output: Contribution to journalArticle

Cofrancesco, Elisabetta ; Boschetti, Carla ; Leonardi, Patrizia ; Gianese, Francesco ; Cortellaro, Michele. / Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia : A randomised, heparin-controlled pilot study. In: Thrombosis Research. 1994 ; Vol. 74, No. 1. pp. 65-75.
@article{c24a0ca317fa48938ed1b1e647dee543,
title = "Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia: A randomised, heparin-controlled pilot study",
abstract = "Efficacy and safety of i.v. dermatan sulphate (DS) and heparin (H) in controlling laboratory alterations due to DIC were compared in 10 patients with acute leukaemia, in a prospective, randomised pilot study. The time courses of the coagulation and fibrinolysis markers for DIC were similar in the two treatment groups except for activated partial thromboplastin time and thrombin time, which were prolonged in the H but not in the DS group. Blood product support tended to be greater in the H than in the DS group. DS appears to be as effective as H in controlling thrombin production during leukaemic cytolysis and may represent a safer alternative to H in the management of DIC in acute leukaemia.",
keywords = "acute leukaemia, dermatan sulphate, DIC, heparin",
author = "Elisabetta Cofrancesco and Carla Boschetti and Patrizia Leonardi and Francesco Gianese and Michele Cortellaro",
year = "1994",
month = "4",
day = "1",
doi = "10.1016/0049-3848(94)90036-1",
language = "English",
volume = "74",
pages = "65--75",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Dermatan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia

T2 - A randomised, heparin-controlled pilot study

AU - Cofrancesco, Elisabetta

AU - Boschetti, Carla

AU - Leonardi, Patrizia

AU - Gianese, Francesco

AU - Cortellaro, Michele

PY - 1994/4/1

Y1 - 1994/4/1

N2 - Efficacy and safety of i.v. dermatan sulphate (DS) and heparin (H) in controlling laboratory alterations due to DIC were compared in 10 patients with acute leukaemia, in a prospective, randomised pilot study. The time courses of the coagulation and fibrinolysis markers for DIC were similar in the two treatment groups except for activated partial thromboplastin time and thrombin time, which were prolonged in the H but not in the DS group. Blood product support tended to be greater in the H than in the DS group. DS appears to be as effective as H in controlling thrombin production during leukaemic cytolysis and may represent a safer alternative to H in the management of DIC in acute leukaemia.

AB - Efficacy and safety of i.v. dermatan sulphate (DS) and heparin (H) in controlling laboratory alterations due to DIC were compared in 10 patients with acute leukaemia, in a prospective, randomised pilot study. The time courses of the coagulation and fibrinolysis markers for DIC were similar in the two treatment groups except for activated partial thromboplastin time and thrombin time, which were prolonged in the H but not in the DS group. Blood product support tended to be greater in the H than in the DS group. DS appears to be as effective as H in controlling thrombin production during leukaemic cytolysis and may represent a safer alternative to H in the management of DIC in acute leukaemia.

KW - acute leukaemia

KW - dermatan sulphate

KW - DIC

KW - heparin

UR - http://www.scopus.com/inward/record.url?scp=0028000981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028000981&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(94)90036-1

DO - 10.1016/0049-3848(94)90036-1

M3 - Article

C2 - 8029809

AN - SCOPUS:0028000981

VL - 74

SP - 65

EP - 75

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 1

ER -